We are live on ! Find out more
CARM

Carisma Therapeutics

Delisted

CARM was delisted on the 10th of October, 2025.

46 hedge funds and large institutions have $78.2M invested in Carisma Therapeutics in 2018 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

614% more capital invested

Capital invested by funds: $10.9M → $78.2M (+$67.2M)

211% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 9

100% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 5

70% more funds holding

Funds holding: 2746 (+19)

40% more call options, than puts

Call options by funds: $1.23M | Put options by funds: $878K

1.4% more ownership

Funds ownership: 1.22%2.62% (+1.4%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
46
Holders Change
+19
Holders Change %
+70.37%
% of All Funds
1.05%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
28
Increased
10
Reduced
5
Closed
9
Calls
$1.23M
Puts
$878K
Net Calls
+$347K
Net Calls Change
+$410K
Name Holding Trade Value Shares
Change
Change in
Stake
PAG
51
Private Advisor Group
New Jersey
-$21K -976 Closed
IWM
52
IHT Wealth Management
Illinois
-$3K -162 Closed
IA
53
IFP Advisors
Florida
-$2K -100 Closed
AIM
54
Advantage Investment Management
Iowa
-$1K -50 Closed
CG
55
Cutler Group
California
+$881 +20 +667%

CARM Hedge Fund Activity: Q2 2018 in Review

46 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2018, worth a combined $78.2M — up 614% from $10.9M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new CARM positions and 9 closed out — a net gain of 19 holders — while 10 added to existing stakes and 5 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $16.6M. The largest seller was Sabby Management, exiting entirely with an estimated $2.7M sold.

  • 46 institutional investors held Carisma Therapeutics (CARM) as of Q2 2018, up from 27 in Q1 2018.
  • Funds reported $78.2M of Carisma Therapeutics stock for Q2 2018, up 614% quarter-over-quarter.
  • 28 funds opened new Carisma Therapeutics positions in Q2 2018 and 9 closed out, a net change of +19 holders.
  • The largest Carisma Therapeutics buyer in Q2 2018 was Consonance Capital Management, an estimated $16.6M added.
  • The largest Carisma Therapeutics seller in Q2 2018 was Sabby Management, an estimated $2.7M sold.

Based on aggregated 13F filings for Q2 2018.